Roxadustat (FG-4592): correction of anemia in incident dialysis patients
A Besarab, E Chernyavskaya, I Motylev… - Journal of the …, 2016 - journals.lww.com
Safety concerns with erythropoietin analogues and intravenous (IV) iron for treatment of
anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an
orally bioavailable hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that promotes
coordinated erythropoiesis through HIF-mediated transcription. We performed an open-
label, randomized hemoglobin (Hb) correction study in anemic (Hb≤ 10.0 g/dl) patients
incident to hemodialysis (HD) or peritoneal dialysis (PD). Sixty patients received no iron, oral …
anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an
orally bioavailable hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that promotes
coordinated erythropoiesis through HIF-mediated transcription. We performed an open-
label, randomized hemoglobin (Hb) correction study in anemic (Hb≤ 10.0 g/dl) patients
incident to hemodialysis (HD) or peritoneal dialysis (PD). Sixty patients received no iron, oral …